The safety and efficacy of zilovertamab vedotin in R/R MCL post-BTKi
Ingrid Glimelius, MD, PhD, Uppsala University, Uppsala, Sweden, comments on the safety and efficacy of zilovertamab vedotin, an antibody-drug conjugate that targets ROR1, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) post-BTK inhibitor (BTKi). She reports a 40% overall response rate and manageable side effects, highlighting the potential of this agent for patients who have become CD20-negative after bispecific antibody therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
